Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic developments in multiple sclerosis.

D S Goodin1

  • 1Department of Neurology, M-794, University of California, San Francisco, CA 94143-0114, USA. dsg@itsa.ucsf.edu

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions.

BMC medical genomics·2021
Same author

Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS.

AJNR. American journal of neuroradiology·2020
Same author

The epidemiology of multiple sclerosis: insights to a causal cascade.

Handbook of clinical neurology·2016
Same author

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.

Multiple sclerosis and related disorders·2015
Same author

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Neurology·2012
Same author

Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society.

Neurology·2012

New multiple sclerosis (MS) treatments like interferon-beta and glatiramer acetate show clinical benefits by reducing disease activity. However, these are partial therapies, necessitating further research into combination treatments and myelin repair for a potential cure.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Significant advancements in MS treatment have emerged, offering new therapeutic options.
  • Current treatments aim to reduce disease activity and clinical relapses.

Purpose of the Study:

  • To review the current state of multiple sclerosis treatment.
  • To evaluate the efficacy of interferon-beta and glatiramer acetate.
  • To discuss future therapeutic strategies for MS.

Main Methods:

  • Review of clinical trial data for interferon-beta and glatiramer acetate.
  • Analysis of magnetic resonance imaging (MRI) outcomes.
  • Discussion of emerging therapeutic approaches and research directions.

Related Experiment Videos

Main Results:

  • Interferon-beta preparations demonstrate well-established efficacy in reducing MS attack rates and disability.
  • Glatiramer acetate also shows therapeutic benefits, supported by available clinical data.
  • Current therapies offer partial disease control but do not represent a cure for MS.

Conclusions:

  • Interferon-beta and glatiramer acetate are important first-line treatments for MS.
  • Further research is needed to develop more effective therapies, potentially including combination treatments.
  • Future strategies may focus on enhancing myelin repair and utilizing combination therapies for improved patient outcomes.